The U.S. Food and Drug Administration has tapped seven pharmaceutical companies — including Eli Lilly and Regeneron — to participate in a pilot program aimed at accelerating the approval process for new domestic drug manufacturing facilities, according to a report from CNBC.
CNBC cited an FDA spokesperson in its Monday report detailing the agency’s selection of the seven firms for the initiative.
